



Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019

Dave Singh¹, Alvar Agusti², Antonio Anzueto³, Peter J. Barnes⁴, Jean Bourbeau⁵, Bartolome R. Celli ⁶, Gerard J. Criner⁷, Peter Frith⁸, David M.G. Halpin⁹, Meilan Han¹⁰, M. Victorina López Varela¹¹, Fernando Martínez¹², Maria Montes de Oca¹³, Alberto Papi ¹⁴, Ian D. Pavord¹⁵, Nicolas Roche¹⁶, Donald D. Sin¹⁷, Robert Stockley¹⁸, Jørgen Vestbo¹, Jadwiga A. Wedzicha⁴ and Claus Vogelmeier¹⁹

 @ERSpublications
The GOLD 2019 report has new pharmacological treatment recommendations, based on recent evidence from clinical trials. Blood eosinophils are recommended as a biomarker to support clinical decisions regarding the use of inhaled corticosteroids. <http://ow.ly/oerU30nSKUX>

Cite this article as: Singh D, Agusti A, Anzueto A, *et al.* Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J* 2019; 53: 1900164 [<https://doi.org/10.1183/13993003.00164-2019>].

ABSTRACT Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of side-effects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD) patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment-naïve individuals at initial presentation. However, their use is more problematic during follow-up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow-up.

Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow-up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.

Received: Jan 23 2019 | Accepted after revision: Feb 22 2019

Copyright ©ERS 2019

Introduction

Chronic obstructive pulmonary disease (COPD) is a complex condition, with many different components and mechanisms contributing to its pathophysiology and clinical presentation [1]. Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information for each individual in order to optimise pharmacological treatment, enabling the therapeutic benefit to be maximised for an individual relative to the possibility of side-effects [1, 2]. For instance, while randomised controlled trials (RCTs) of inhaled corticosteroid (ICS)-containing combinations have consistently demonstrated a clinical benefit for the ICS component on a group basis, the presence and magnitude of effect varies greatly between individuals [3]. Furthermore, there are concerns about the long-term side-effects of ICS use in COPD, in particular pneumonia but also osteoporosis, diabetes, tuberculosis and non-tuberculous mycobacteria infection [1, 3].

Eosinophilic airway inflammation is present in a subset of COPD patients [4, 5]. Short-term clinical trials have shown that higher sputum eosinophil counts in stable COPD patients predict a greater lung function response to corticosteroids [6, 7]. Sputum eosinophil measurement is not widely available in most centres, limiting its use in daily clinical practice, and patients cannot always provide adequate samples for analysis. Blood eosinophil measurements are an alternative biomarker reflecting eosinophilic airway inflammation in COPD patients [4]. Recent clinical trials have shown that blood eosinophil counts are associated with the efficacy of ICSs in COPD patients [8–13], suggesting the use of this biomarker to identify individuals with a greater probability of treatment benefit with ICSs. This provides an opportunity in clinical practice to target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 strategy document recommended that an assessment (ABCD grouping) based on symptoms and exacerbation risk should be performed after the initial diagnosis of COPD [14]. The ABCD grouping was designed to facilitate a more individualised approach to pharmacological management based on clinical characteristics, with different recommendations for initial treatment and subsequent follow-up for each group [14]. While these treatment algorithms can be applied relatively easily to treatment-naïve individuals at initial presentation, their use is more problematic during follow-up in patients who are already on maintenance treatment. One key issue is that the grouping applied to an individual may change over time, which could reflect either a positive response to treatment or worsening of disease [15]. A potential solution is to use ABCD *only for initial treatment*, and use a different system to guide pharmacological management in COPD patients who are in follow-up and already receiving treatment.

Recent large RCTs focusing on exacerbation prevention have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators [9, 10, 16]. This article explains the GOLD Science Committee's interpretation of the evidence for blood eosinophils as a biomarker in COPD patients and recent RCT evidence concerning exacerbation prevention. We explain how this information was incorporated into the GOLD 2019 recommendations, which set out to provide more clarity regarding initial and follow-up pharmacological management [17].

Initial and follow-up pharmacological management; more clarity needed in GOLD

GOLD 2017 pharmacological treatment recommendations were based on the ABCD categorisation of patients at diagnosis [14]. Using this system to decide on an initial treatment plan is relatively straightforward. Following the relevant algorithm to decide on the next steps after initial treatment requires knowledge of the

Affiliations: ¹University of Manchester, Manchester, UK. ²Hospital Clínic, Universitat de Barcelona, CIBERES, Barcelona, Spain. ³University of Texas Health Science Center, San Antonio, TX, USA. ⁴National Heart and Lung Institute, London, UK. ⁵McGill University Health Centre, Montreal, QC, Canada. ⁶Brigham and Women's Hospital Boston, Boston, MA, USA. ⁷Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. ⁸Flinders University College of Medicine and Public Health, Adelaide, Australia. ⁹Royal Devon and Exeter Hospital, Exeter, UK. ¹⁰University of Michigan School of Medicine, Ann Arbor, MI, USA. ¹¹Universidad de la República Montevideo, Montevideo, Uruguay. ¹²New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA. ¹³Universidad Central de Venezuela, Caracas, Venezuela. ¹⁴Cardiorespiratory and Internal Medicine Unit, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy. ¹⁵Respiratory Medicine Unit, Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, Oxford, UK. ¹⁶Hôpital Cochin (AP-HP), University Paris Descartes, Paris, France. ¹⁷University of British Columbia, Vancouver, BC, Canada. ¹⁸University Hospital, Birmingham, UK. ¹⁹Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps University Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.

Correspondence: Dave Singh, University of Manchester, Medicines Evaluation Unit, The Langley Building, Manchester University NHS Foundation Hospital Trust, Southmoor Road, Manchester, M23 9QZ, UK. E-mail: dsingh@meu.org.uk

clinical response to the previous treatment, which guides whether to escalate, switch, de-escalate or maintain the current regimen [15]. These important details regarding the response to previous treatment may be lost when the GOLD 2017 treatment algorithms are applied for the first time to a COPD patient who is already on maintenance inhaled treatment. Furthermore, a beneficial response to the previous treatment may lead to changes in the GOLD ABCD grouping and the clinician may be confused about whether this change should lead to the subsequent withdrawal of a beneficial pharmacological treatment. COPD patients can change their GOLD group over time [18] and in such situations it is unclear how the ABCD system should be used.

GOLD 2019 retains the ABCD grouping to decide on appropriate *initial* pharmacological treatment (figure 1) [17]. However, GOLD 2019 states that the ABCD grouping *should not be used* for patients who are already on maintenance treatment. To make clearer recommendations for such patients, distinct treatment pathways have been constructed for pharmacological management during follow-up (figure 2). Symptoms (dyspnoea and exercise limitation) and exacerbations are still the focus of treatment, and there are separate algorithms for each of these treatable traits [19]. The clinician needs to decide the predominant trait that requires further effective treatment at that point in time and use the relevant algorithm; the exacerbation algorithm should be used for patients suffering with both symptoms and exacerbations. The patient should be placed within the relevant algorithm according to their current treatment and recommendations for treatment escalation, switching or de-escalation utilised.

Both follow-up treatment algorithms include all the currently available inhaled monotherapy and combination treatment classes, in order to encompass all previous treatment possibilities. This explains why ICS/long-acting β_2 -agonist (LABA) is included in the dyspnoea algorithm; it is not recommended as a treatment for dyspnoea (as no escalation arrow leads towards this treatment), but is included for those patients who are currently being treated with ICS/LABA and now have dyspnoea that needs further treatment. Similarly, LABAs or long-acting muscarinic antagonists (LAMAs) are stated at the top of each algorithm to cover both of these previous treatment possibilities. The most appropriate treatment algorithm to use should be re-evaluated at each clinic visit, as these pathways have been constructed so that the patient can be switched from one to the other as appropriate.

The dyspnoea algorithm recommends escalation using additional long-acting bronchodilator treatment for breathlessness and closely follows the recommendations of the GOLD 2017 report, albeit in a different format. For patients with dyspnoea who are already treated with a dual bronchodilator or triple combination, the option to switch molecules or inhaler device has been added, and there is a reminder to investigate other possible causes of dyspnoea such as heart failure and pulmonary hypertension. Non-pharmacological management approaches including pulmonary rehabilitation should also be considered. The exacerbation pathway recommendations differ from the GOLD 2017 report in both scientific content and format, due to the incorporation of blood eosinophils as a biomarker and recent evidence from RCTs.

The evidence for blood eosinophils as a biomarker in COPD

Relationship of blood to lung eosinophils

Bronchoscopic and sputum sampling shows the presence of increased eosinophil numbers in some COPD patients [4, 20], promoting the concept of a subgroup of patients with “eosinophilic COPD” due to the




FIGURE 1 Global Initiative for Chronic Obstructive Lung Disease 2019 recommendations for initial pharmacological management in chronic obstructive pulmonary disease (COPD). LAMA: long-acting muscarinic antagonist; LABA: long-acting β_2 -agonist; ICS: inhaled corticosteroid; CAT: COPD Assessment Test; eos: blood eosinophil count ($\text{cells}\cdot\mu\text{L}^{-1}$); mMRC: modified Medical Research Council dyspnoea questionnaire. Reproduced with permission from [17].




FIGURE 2 Global Initiative for Chronic Obstructive Lung Disease 2019 recommendations for follow-up pharmacological management. LABA: long-acting β_2 -agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid; FEV₁: forced expiratory volume in 1 s. Reproduced with permission from [17].

increased number of these cells in the airways. There is a statistical correlation between blood and sputum eosinophil numbers in COPD patients, although the relationship remains moderate to weak [5, 21, 22]. However, sputum eosinophil counts are prone to considerable intersample variability [23, 24] and should not be regarded as the “gold standard” biomarker of eosinophilic lung inflammation. Higher blood eosinophil counts are associated with greater eosinophil counts in lung tissue samples [4, 25] and pathological differences including increased reticular basement membrane thickening (subepithelial fibrosis) [4].

Variability of blood eosinophils

Factors that can influence blood eosinophil counts include sepsis and oral corticosteroids, which reduce counts [5]. The intraclass correlation coefficient (ICC) of repeat blood eosinophil counts is reported as 0.64 at 1 year (n=17724), increasing to 0.70 when excluding patients where oral corticosteroid use and/or concurrent exacerbations may have influenced counts [26], 0.87 at >2 years (n=59) [27] and 0.57 at 3 years (n=1483) [28]. ICC values can be interpreted as excellent (>0.75), fair to good (0.40–0.75) or poor (<0.40) [26]. These ICC values for repeated blood eosinophil counts in COPD patients, therefore, lie in the fair to good or excellent categories and are similar to reported values for cholesterol (ICC 0.70–0.72) and glycated haemoglobin (HbA1c; ICC 0.59), which are commonly used biomarkers in the management of other diseases [26]. It should be noted that cholesterol and HbA1c are biomarkers used to monitor the effects of pharmacological interventions, while this article discusses the use of blood eosinophil counts in COPD to predict pharmacological effects.

Analysis of the number of patients that cross a predetermined threshold over time shows good stability at lower threshold values [5]. Using the <150 eosinophils- μL^{-1} threshold, 87% and 86% of results remained stable at 6 months and >2 years, respectively [27]. Greater variability has been observed with higher threshold values, e.g. using 340 cells- μL^{-1} , stability was 85% at 6 months and 62% at 2 years [29]. The

variability observed with multiple testing (at least three measurements) [26] remains greater at higher eosinophil counts; 88% with a first blood eosinophil count ≥ 150 cells- μL^{-1} had a subsequent mean value ≥ 150 cells- μL^{-1} , while for a first count ≥ 300 cells- μL^{-1} the proportion with a subsequent mean above this level was 68% [26]. For the >300 eosinophils- μL^{-1} threshold, observational cohorts report that 15.8%, 19% and 20% of values are always above this level after 1 or 2 years of follow-up, with the proportion at a single measurement being higher [27, 30, 31]. The percentage of COPD patients identified above or below given blood eosinophil thresholds may be influenced by geographical variations.

Blood eosinophils and ICS response

Post hoc and pre-specified analyses of RCTs have evaluated the relationship between blood eosinophil counts measured before randomisation and ICS effects. The evidence from these studies is reviewed according to treatment comparison. Unless stated otherwise, the inclusion criteria of all these studies required patients to have one or more moderate or severe exacerbations in the previous year and the studies were of at least 1 year duration.

ICS/LABA versus LABA

Three *post hoc* analyses of RCTs that compared ICS/LABA *versus* LABA all showed a similar pattern of results [11, 12, 32]; there was a continuous relationship between blood eosinophil counts and the effect of ICS on exacerbation prevention, with higher eosinophil counts predicting a greater drug response. The largest analysis (n=4528) used data modelling to demonstrate that no benefit of ICS was observed at <100 eosinophils- μL^{-1} , with the effect at higher counts being larger (and more likely clinically relevant) [32]; the treatment effect at >300 cells- μL^{-1} in this and other analyses was $\sim 50\%$ exacerbation rate reduction [11, 12]. The data modelling analyses also showed greater ICS effects at higher blood eosinophil counts for forced expiratory volume in 1 s (FEV₁) and quality of life.

Post hoc analyses of other studies comparing ICS/LABA *versus* LABA that have used a single blood eosinophil threshold have been less informative [33]. Trying to dichotomise a COPD population using a single eosinophil threshold to define “responders” and “non-responders” is overly simplistic in this situation, as different eosinophil thresholds appear to reflect different magnitudes of ICS response: <100 cells- μL^{-1} is associated with little or no effect, while relatively large effects are observed at >300 cells- μL^{-1} (figure 3). This is similar to a classical pharmacological dose–response curve with drug concentration on the x-axis and drug response on the y-axis, except here the x-axis is the blood eosinophil count.

Triple-therapy studies (LABA/LAMA/ICS fixed combination)

In the TRIBUTE study, a pre-specified analysis showed a greater effect of triple therapy (beclomethasone dipropionate/formoterol/glycopyrrolate) *versus* LAMA/LABA (glycopyrrolate/indacaterol) on exacerbation rate reduction in patients with blood eosinophils $\geq 2\%$ (20% treatment difference; $p=0.029$) compared with $<2\%$ (6%; $p=0.68$) [10]. Numerically similar results were obtained using ≥ 200 cells- μL^{-1} , although statistically significant benefit was not reached above this threshold ($p=0.057$).

The IMPACT study enrolled patients with FEV₁ $<50\%$ predicted and one or more moderate or severe exacerbations in the previous year, or FEV₁ 50–80% predicted and two or more moderate exacerbations or one severe exacerbation in the previous year [9]. These inclusion criteria enrolled a population with a relatively high exacerbation risk; 54% had two or more moderate or severe exacerbations and 26% had one




FIGURE 3 The relationship between blood eosinophil count and the effect of inhaled corticosteroid (ICS) on exacerbation prevention in chronic obstructive pulmonary disease patients.

or more severe exacerbations in the previous year. There was a 25% treatment difference in the annual exacerbation rate in favour of triple therapy (fluticasone furoate/vilanterol/umeclidinium) over LAMA/LABA (umeclidinium/vilanterol). A pre-specified analysis showed a 32% treatment difference ($p < 0.001$) at ≥ 150 eosinophils- μL^{-1} , while below this threshold the treatment difference was smaller, but still significantly in favour of triple therapy (12%; $p = 0.034$).

ICS/LABA versus LABA/LAMA

The FLAME study showed that LAMA/LABA (glycopyrrolate/indacaterol) had a 17% greater effect on exacerbation rate reduction than ICS/LABA (fluticasone propionate/salmeterol) [34]. Pre-specified analysis using a 2% eosinophil threshold showed no difference in treatment effect above or below this threshold [34]. Subsequent *post hoc* analysis using three subgroups (< 150 , $150 - < 300$ and ≥ 300 cells- μL^{-1}) revealed a different pattern of results [35]; LABA/LAMA had a much greater effect than ICS/LABA at < 150 cells- μL^{-1} (28% difference; $p < 0.001$), but at $150 - < 300$ and ≥ 300 cells- μL^{-1} this treatment comparison yielded smaller differences (11% and 7%, respectively). Patients with higher eosinophil counts (> 600 cells- μL^{-1}) were excluded, possibly blunting the result in the > 300 cells- μL^{-1} category. This analysis supports the concept of a continuous relationship between blood eosinophils and ICS effects, with reduced ICS effects at lower blood eosinophil counts. In this study, the previous exacerbation history did not influence the treatment differences [35, 36], although the proportion of patients with a history of at least two exacerbations in the previous year was limited (~20%).

The IMPACT study also compared ICS/LABA (fluticasone furoate/vilanterol) with LAMA/LABA; ICS/LABA had a 10% greater effect on exacerbation prevention in the overall population. The treatment difference was dependent on blood eosinophil counts, with LAMA/LABA having a greater effect at < 150 cells- μL^{-1} , while ICS/LABA had a greater effect above this threshold. These results differ significantly from FLAME, where ICS/LABA was not superior to LAMA/LABA in any eosinophil threshold or subgroup analysis [35]. A key difference between these studies was the exacerbation risk of the enrolled populations, as most of the FLAME population had one exacerbation in the previous year [34], in contrast to the much higher risk of the IMPACT population, indicating that the effects of ICS-containing combinations are greater in higher-risk populations. Patients with a history of asthma were excluded from FLAME but were allowed to participate in IMPACT, potentially influencing the observed ICS treatment effects. The run-in treatment in the FLAME study was tiotropium, while in the IMPACT study patients continued with their own inhaled treatment. This also may have contributed to the differing results, as some patients requiring ICS would have dropped out during the FLAME run-in period.

ICS step-down studies

The WISDOM study evaluated the stepped withdrawal of ICS from triple therapy. Two *post hoc* analyses of WISDOM have shown a significant deleterious effect of ICS withdrawal at higher blood eosinophil counts (≥ 300 cells- μL^{-1}) [8, 37]. One of these analyses showed a greater deleterious effect in patients with a prior history of two or more exacerbations, supporting the concept of greater ICS effects in higher exacerbation risk individuals. The SUNSET study enrolled patients with zero or one exacerbation (66% and 34%, respectively) in the previous year who were already on triple therapy for at least 6 months [38]. ICS withdrawal appeared to be well tolerated at < 300 eosinophils- μL^{-1} , while a clinical deterioration (greater lung function loss) and more exacerbations were observed in those with ≥ 300 eosinophils- μL^{-1} .

Other clinical trials

Post hoc analysis of the INSPIRE study did not show any significant differences between ICS/LABA versus LAMA using thresholds of 2% and 200 cells- μL^{-1} , but other thresholds were not investigated [33]. A combined analysis of 10 studies showed that pneumonia risk was higher in patients with eosinophils $< 2\%$ independent of ICS use, although the effect size was small (3.7% versus 3.2%; hazard ratio 1.31, 95% CI 1.06–1.62) [39]. A clinical trial reported that blood eosinophil counts may predict which patients receive benefit from oral corticosteroid treatment during exacerbations [40]. These data may help direct acute exacerbation management, but do not provide support for the use of blood eosinophils to help direct the use of ICS-containing combination inhalers.

Summary: blood eosinophils and ICS response

The clinical evidence reviewed contains subgroup analyses with reduced sample sizes. In such cases, a focus on p-values for statistical significance may be less appropriate. However, the magnitude of effect sizes and consistency of data between studies become important considerations. A consistent pattern of results from RCTs conducted in COPD patients at increased risk of exacerbations has emerged, showing that lower eosinophil counts predict a lower or no benefit of ICS in terms of exacerbation prevention, which is particularly evident below approximately 100 eosinophils- μL^{-1} . The greatest ICS effects were

consistently observed at ≥ 300 eosinophils- μL^{-1} . These thresholds of <100 and ≥ 300 eosinophils- μL^{-1} can therefore be used to help predict the likelihood and magnitude of ICS treatment benefit in clinical practice. These thresholds provide a measure of probability that can be used with other clinical information, notably exacerbation risk, to estimate the likelihood of a benefit from ICS treatment.

The different results observed when comparing the double combination treatments in the FLAME and IMPACT studies highlight that ICSs have a greater demonstrable benefit in higher exacerbation risk populations. This can influence the interpretation of blood eosinophil counts and thresholds. In patients with one moderate exacerbation in the previous year, the FLAME results indicate that LAMA/LABA is generally a preferred treatment, although ICS/LABA may be a more effective treatment for some patients with eosinophils ≥ 300 cells- μL^{-1} . In higher-risk patients (two or more moderate exacerbations or one severe exacerbation), the IMPACT study demonstrated that the benefits of ICS/LABA over LAMA/LAMA were present even at lower blood eosinophil counts, indicating that ICS/LABA use could be considered in high-risk patients at >100 eosinophils- μL^{-1} , while being preferred at higher eosinophil counts.

The number needed to treat (NNT) to prevent one exacerbation (event-based NNT) is dependent on the underlying exacerbation rate and has been approximately derived from the IMPACT results; the NNT to prevent one exacerbation with triple therapy compared with LAMA/LABA (where a 25% reduction in exacerbation rate was observed) has been estimated to lie between 3 and 4 [3]. These event-based NNTs will vary with blood eosinophil counts, being lower at the higher eosinophil counts where greater ICS effects were observed. The event-based NNT is dependent on the comparator rate of exacerbations and so will change according to the exacerbation risk of a population. The TRIBUTE study population had a lower exacerbation risk as reflected in the previous 1-year history compared with the IMPACT population and consequently a lower rate of exacerbations was observed during the study, with a 15% difference between triple therapy and LAMA/LABA for exacerbation rate reduction. The event-based NNT calculation for this study estimates the value to lie between 11 and 12 [3], with a lower number expected at higher eosinophil counts. The person-based NNT (*i.e.* to make a patient exacerbation free) for IMPACT and TRIBUTE has been estimated to be 25 and 50, respectively, for triple therapy *versus* LAMA/LABA. These NNT estimates emphasise that exacerbation risk influences the magnitude of ICS effects on exacerbation prevention.

Blood eosinophils are a peripheral biomarker of airway eosinophil numbers and eosinophil-associated airway inflammation such as type 2 cytokines and reticular basement membrane thickening [4]. The clinical benefits of ICSs reported in COPD RCTs do not arise from suppression of blood eosinophil numbers, but are presumably due to pharmacological effects on a component/components of airway inflammation that are associated with higher blood eosinophil counts.

Overall, current evidence indicates that the individual assessment of exacerbation risk and blood eosinophil count can be combined to help predict the likelihood of clinical benefit with ICS-containing combinations. This should be coupled with an individualised assessment of the risk of side-effects, notably pneumonia, mycobacterial infection, osteoporosis, diabetes and cataracts.

Relationship of blood eosinophils to clinical characteristics

Cohort studies have investigated whether blood eosinophil counts are associated with clinical characteristics, such as exacerbation rates. The results have varied, with both negative and positive findings reported for exacerbations [30, 41, 42]. A recent publication using both cross-sectional (at baseline) and prospective data from COPDGene and ECLIPSE showed that eosinophils ≥ 300 cells- μL^{-1} are associated with increased exacerbation risk [28], with the findings being most clearly demonstrated in patients at high exacerbation risk (two or more exacerbations in the previous year). This highlights that exacerbation risk, according to the history of exacerbations, influences the results of these cohort studies. Also, the study showed that an increased blood eosinophil count in COPD was not the same as stating that the patient had asthma-COPD overlap as the overlap between the two was small. Furthermore, the clinical trials already reviewed of ICS/LABA *versus* LABA in COPD patients with a history of exacerbations showed that ICS use reduces exacerbation rates in patients with more eosinophils, and the relationship between eosinophil counts and exacerbation rates was only seen without ICS use. Overall, the confounding factors of ICS treatment effect and clinical exacerbation risk are responsible for the heterogeneity between studies. These inconsistent data do not support the use of blood eosinophils as a biomarker to predict exacerbation risk or other clinical outcomes in the general COPD population.

New evidence from clinical trials

The TRIBUTE and IMPACT studies comparing triple therapy *versus* LAMA/LABA provided, for the first time, evidence of the beneficial effect of the ICS component of triple therapy on exacerbations (15% and 25% exacerbation rate reduction, respectively) and quality of life [9, 10]. IMPACT also reported a different

result to FLAME [34] for the comparison of double combinations, which can be attributed mainly to the different exacerbation risk of the study populations as already discussed. These results from the TRIBUTE and IMPACT studies provide evidence to support the GOLD 2017 recommendation to escalate from LAMA/LABA to triple therapy. In contrast, the situation concerning double combinations has now been shown to be more complex, as the relative efficacy of double combinations is influenced by both exacerbation risk (and hence study enrichment regarding exacerbation history) and blood eosinophil count.

The DYNAGITO study compared the effect of LAMA/LABA (tiotropium/olodaterol) *versus* LAMA (tiotropium) on exacerbation prevention in patients with one or more exacerbations in the previous year (n=7880) [16]. A reduction of only 7% (p=0.0498) in the exacerbation rate in favour of LAMA/LABA was observed, which did not meet the *a priori* level set for significance (0.01). The only similar previous study was SPARK, which showed that LAMA/LABA (glycopyrrolate/indacaterol) reduced moderate to severe exacerbations by 12% (p=0.038) *versus* glycopyrrolate (the primary outcome) and 10% (p=0.096) *versus* open-label tiotropium. Overall, DYNAGITO and SPARK demonstrate a minor additional effect of the LABA component of dual bronchodilator therapy on exacerbation prevention.

Implementing new evidence into GOLD 2019

Initial pharmacological management

The large RCTs in COPD have usually been conducted in populations where the majority of individuals were already taking maintenance treatment before entering the study. Few studies have been specifically designed to evaluate pharmacological interventions in treatment-naïve COPD patients. The GOLD recommendations for initial pharmacological treatment are based on existing evidence, but with the limitation that these recommendations have not been directly tested in treatment-naïve populations.

The lack of new RCTs in treatment-naïve COPD patients means that the GOLD 2019 initial treatment recommendations (figure 1) are mostly similar to GOLD 2017. The exception is GOLD group D, with two key changes. First, eosinophils ≥ 300 cells· μL^{-1} is suggested as an indicator to consider ICS/LABA treatment, as this threshold identifies patients with a higher likelihood of benefit from ICS treatment. A retrospective analysis of real-world clinical practice data supports this recommendation; the effects of ICS/LABA as an initial treatment on exacerbation prevention were greater than LAMA treatment in patients with eosinophils ≥ 300 cells· μL^{-1} , but not below this threshold [43]. Second, a box stating that LAMA/LABA is a preferred treatment in GOLD 2017 has been removed due to the new evidence on exacerbation prevention showing that the magnitude of effect of LAMA/LABA over LAMA was smaller than expected (DYNAGITO) [16] and that ICS/LABA is a better treatment than LAMA/LABA in some patients (IMPACT) [9]. RCTs have demonstrated the benefits of LAMA/LABA compared with LAMA monotherapy for symptoms and quality of life [44, 45], so there is a practical recommendation to consider LAMA/LABA as first-line therapy in more highly symptomatic individuals.

Follow-up pharmacological management

The dyspnoea pathway (figure 2) closely follows the GOLD 2017 recommendations for groups B and D, using additional long-acting bronchodilator treatment to manage symptoms. In contrast, the follow-up exacerbation pathway is very different, as the integration of exacerbation risk and blood eosinophil counts influences the recommendations regarding the use of combination inhalers. For escalation from long-acting bronchodilator monotherapy to either ICS/LABA or LAMA/LABA, the threshold of ≥ 300 eosinophils· μL^{-1} can be used across all COPD patients who require further treatment to prevent exacerbations to favour the choice of ICS/LABA. A lower threshold (>100 eosinophils· μL^{-1}) may be used in patients at high exacerbation risk (two or more moderate exacerbations or one severe exacerbation in the previous year) to support ICS/LABA use, as ICS effects appear to be greater in such high-risk individuals.

The GOLD 2019 report uses the word “consider” when making treatment recommendations concerning blood eosinophils for two reasons: 1) this biomarker provides a degree of probability (not certainty) regarding whether ICS treatment will be beneficial and the magnitude of effect, and 2) other clinical characteristics including the risk of side-effects must also be considered on an individual basis.

For patients already taking LAMA/LABA who are still having exacerbations, we suggest the threshold of >100 eosinophils· μL^{-1} to identify individuals with a greater likelihood of achieving clinical benefit when escalating to triple therapy. The continuous nature of the relationship between blood eosinophil counts and ICS benefits means that the magnitude of effect on exacerbations will be greater at higher eosinophil counts, particularly ≥ 300 eosinophils· μL^{-1} . For patients with <100 eosinophils· μL^{-1} , the escalation to triple therapy is unlikely to have a major influence on exacerbations. Other options include the addition of roflumilast or azithromycin [46, 47].




FIGURE 4 Global Initiative for Chronic Obstructive Lung Disease 2019 management cycle recommendations. Reproduced with permission from [17].

Advice is provided regarding the discontinuation of ICS, either by the de-escalation from triple therapy to LAMA/LABA or switching from ICS/LABA to LAMA/LABA. The common clinical scenarios when this may be considered are 1) concerns about side-effects (e.g. likelihood and impact of pneumonia), 2) inappropriate original indication (e.g. the patient had no history of exacerbations and ICS had been prescribed to manage symptoms) and 3) lack of response to ICS. The withdrawal of ICS should be closely monitored, with evidence indicating that the greatest probability of a deleterious effect is in patients with ≥ 300 eosinophils- μL^{-1} .

An important addition to the pharmacological management section is the management cycle (figure 4), which describes the process of review of symptoms and exacerbations followed by assessment of inhaler technique and adherence as well as non-pharmacological approaches including pulmonary rehabilitation and self-management education. Assessing, treating and following comorbidities also need to be considered throughout the management cycle. This provides a wider holistic view of the many factors to be evaluated before deciding whether to adjust pharmacological treatment.

Conclusions

The changes to GOLD 2019 reflect an evolution based on recent evidence, rather than change of direction, towards a more personalised approach to COPD management advocated in previous GOLD reports. The focus on managing symptoms and reducing exacerbation risk remains the same. Blood eosinophils have been added in order to help clinicians better manage decisions regarding the benefits *versus* risks of using ICS. Blood eosinophils provide information regarding probability of benefit and the interpretation of this information is clearer in patients with high exacerbation risk. Clinical decisions regarding the use of ICS-containing combination treatments must focus on exacerbation risk, supported by eosinophil biomarker information, and evaluate side-effect risk for each individual.

GOLD 2019 pharmacological treatment recommendations often provide more than one choice, as evidence has shown these to be effective options. This creates complexity in decision making, in contrast to the simplicity of recommending only one treatment option in each situation. However, the heterogeneity of COPD patients means that treatment recommendations and algorithms should allow flexibility for the individual clinical characteristics and needs of each patient to be taken into account, as well as differences between healthcare systems. GOLD 2019 attempts to provide flexibility in this context, allowing different treatment choices and also providing a framework to help clinicians choose. The area of most debate and complexity is the use of combination inhalers to prevent exacerbations. Recent clinical evidence shows that each of these combination inhalers can be regarded as optimum treatments in some patients, who can be identified using clinical characteristics and a blood biomarker [9, 10]. Individualisation of COPD pharmacological treatment has progressed significantly since the days of FEV₁-guided pharmacological management [48].

Acknowledgements: D. Singh and J. Vestbo are supported by the NIHR Manchester Biomedical Research Centre. This report from the GOLD science committee is not the GOLD Executive Summary.

Conflict of interest: D. Singh reports grants and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work. A. Agusti reports personal fees from AstraZeneca, Chiesi and Nuvaair, grants and personal fees from Menarini and GlaxoSmithKline, outside the submitted

work. A. Anzueto reports grants and personal fees for consultancy from GlaxoSmithKline, personal fees for consultancy from AstraZeneca, Novartis, Boehringer Ingelheim and Sunovion Pharmaceutical, outside the submitted work. P.J. Barnes reports grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees from Pieris, Novartis and Teva, outside the submitted work. J. Bourbeau reports grants from CIHR, Canadian Respiratory Research Network (CRRN), Foundation of the MUHC and Aerocrine, personal fees for consultancy and lecturing from the Canadian Thoracic Society and CHEST, grants and personal fees for advisory work and lecturing from AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, Novartis and Trudell, outside the submitted work. B.R. Celli reports grants and research support from AstraZeneca, personal fees for consulting and scientific committee membership from GlaxoSmithKline, personal fees for consulting from Boehringer Ingelheim, Novartis, Sanofi-Aventis and Menarini, outside the submitted work. G.J. Criner reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Mereo, AstraZeneca, Pulmonx, Pneumrx, Olympus, Broncus, Lungpacer, Nuvaira, ResMed, Respiroics and Patara, personal fees from Verona, BTG, EOLO and NGM, grants from Alung, Fisher Paykel and Galapagos, outside the submitted work. P. Frith reports non-financial support to attend a scientific committee meeting from Global Initiative for Chronic Obstructive Lung Disease (GOLD), during the conduct of the study; personal fees for advisory board membership from AstraZeneca, personal fees and non-financial support for advisory board work, chairing independent conference organising committees and lecturing from Boehringer Ingelheim and Novartis, non-financial support for attending educational meetings from GlaxoSmithKline, non-financial support for attending committee and board meetings from Lung Foundation Australia (LFA), personal fees and non-financial support for advisory board work from CSL Behring, outside the submitted work. D.M.G. Halpin reports personal fees and non-financial support from Boehringer Ingelheim and Novartis, personal fees from AstraZeneca, Chiesi, GlaxoSmithKline and Pfizer, outside the submitted work. M. Han reports personal fees from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, research support from Novartis and Sunovion, outside the submitted work. M.V. López Varela has nothing to disclose. F. Martinez reports personal fees for organising CME programmes and non-financial support for travel from the American College of Chest Physicians, Continuing Education, Inova Fairfax Health System, MD Magazine, Miller Communications, National Association for Continuing Education, PeerView Communications, Prime Communications, Puerto Rican Respiratory Society, Potomac, University of Alabama Birmingham, Physicians Education Resource and Canadian Respiratory Network, personal fees for advisory board and steering committee work, and lecturing, and non-financial support for travel from AstraZeneca, personal fees for advisory board and data safety and monitoring board work, and lecturing, non-financial support for travel from Boehringer Ingelheim, non-financial support for advisory board work from ProterrixBio, personal fees for organising CME programmes from Columbia University Integrity, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Western Connecticut Health Network, Academic CME, PlatformIQ, Rockpointe, Rare Disease Healthcare Communications and France Foundation, personal fees for advisory board work and non-financial support for travel from ConCert, Roche, Sunovion, Theravance and Teva, personal fees for advisory board and data safety and monitoring board work and non-financial support for travel from Genentech, personal fees for advisory board, steering committee and data safety and monitoring board work, and lecturing, and non-financial support for travel from GlaxoSmithKline, personal fees for advisory board work and lecturing, and non-financial support for travel from Novartis and Chiesi, personal fees for advisory board and steering committee work, and non-financial support for travel from Pearl Pharmaceuticals, personal fees for teleconference involvement from Unity, non-financial support for steering committee work from Afferent/Merck, Gilead, Veracyte, Prometic, Bayer and ProMedior, non-financial support for teleconferencing and steering committee work from Nitto, personal fees for consultancy and steering committee work from Patara, non-financial support for data safety and monitoring board work and steering committee from Biogen, personal fees for advisory board work and support for meeting attendance from Zambon, personal fees for editorial board work from the American Thoracic Society, grants from NIH (IPF UO1, COPD UO1/RO1), and non-financial support for consultancy from Bridge Biotherapeutics, outside the submitted work. M. Montes de Oca has nothing to disclose. A. Papi reports grants, personal fees for board membership, consultancy, lecturing and travel reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and Teva, grants, personal fees for lecturing and travel reimbursement from Menarini, personal fees for lecturing and travel reimbursement from Novartis, Zambon and Sanofi, outside the submitted work. I.D. Pavord reports personal fees for lecturing, advisory board work and travel expenses from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Teva, grants and personal fees for lecturing, advisory board work and travel expenses from Chiesi, personal fees for advisory board work from Sanofi/Regeneron, Merck, Novartis, Knopp and Roche/Genentech, personal fees for lecturing from Circassia and Mundipharma, grants and personal fees for advisory board work from Afferent, outside the submitted work. N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M and Zambon, outside the submitted work. D.D. Sin reports grants from Merck, personal fees for advisory meetings from Sanofi-Aventis and Regeneron, grants and personal fees for lecturing and advisory board work from Boehringer Ingelheim and AstraZeneca, personal fees for lecturing and advisory board work from Novartis, outside the submitted work. R. Stockley reports personal fees for advisory board membership and lecturing from AstraZeneca, personal fees for advisory board membership from MedImmune, Almirall, Kamada, Baxter, Chiesi and Polyphor, personal fees for lecturing from Nycomed, Takeda and GlaxoSmithKline, personal fees for advisory board membership, lecturing and travel to meetings from Boehringer Ingelheim, grants and personal fees for advisory board membership, lecturing and travel to meetings from CSL Behring, outside the submitted work. J. Vestbo reports personal fees for consultancy and lecturing from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, grants from Boehringer Ingelheim, outside the submitted work. J.A. Wedzicha reports grants and travel expenses from GlaxoSmithKline, Boehringer Ingelheim, Novartis and AstraZeneca, and grants from Johnson and Johnson, and Chiesi, outside the submitted work. C. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work.

References

- 1 Singh D, Roche N, Halpin D, *et al.* Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2016; 194: 541–549.

- 2 Woodruff PG, Agusti A, Roche N, *et al.* Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. *Lancet* 2015; 385: 1789–1798.
- 3 Agusti A, Fabbri LM, Singh D, *et al.* Inhaled corticosteroids in COPD: friend or foe? *Eur Respir J* 2018; 52: 1801219.
- 4 Kolsum U, Damera G, Pham TH, *et al.* Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol* 2017; 140: 1181–1184.
- 5 Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? *Lancet Respir Med* 2017; 5: 747–759.
- 6 Brightling CE, McKenna S, Hargadon B, *et al.* Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. *Thorax* 2005; 60: 193–198.
- 7 Brightling CE, Monteiro W, Ward R, *et al.* Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2000; 356: 1480–1485.
- 8 Calverley PMA, Tetzlaff K, Vogelmeier C, *et al.* Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017; 196: 1219–1221.
- 9 Lipson DA, Barnhart F, Brealey N, *et al.* Once-daily single-inhaler triple *versus* dual therapy in patients with COPD. *N Engl J Med* 2018; 378: 1671–1680.
- 10 Papi A, Vestbo J, Fabbri L, *et al.* Extrafine inhaled triple therapy *versus* dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet* 2018; 391: 1076–1084.
- 11 Pascoe S, Locantore N, Dransfield M, *et al.* Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med* 2015; 3: 435–442.
- 12 Siddiqui SH, Guasconi A, Vestbo J, *et al.* Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 523–525.
- 13 Vestbo J, Papi A, Corradi M, *et al.* Single inhaler extrafine triple therapy *versus* long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet* 2017; 389: 1919–1929.
- 14 Vogelmeier CF, Criner GJ, Martinez FJ, *et al.* Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med* 2017; 195: 557–582.
- 15 Singh D, Barnes PJ, Stockley R, *et al.* Pharmacological treatment of COPD: the devil is always in the detail. *Eur Respir J* 2018; 51: 1800263.
- 16 Calverley PMA, Anzueto AR, Carter K, *et al.* Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. *Lancet Respir Med* 2018; 6: 337–344.
- 17 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019. <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf> Date last accessed: March 6, 2019.
- 18 Faner R, Noell G, Badia JR, *et al.* Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. *Respir Med* 2018; 141: 14–19.
- 19 Agustí A, Bafadhel M, Beasley R, *et al.* Precision medicine in airway diseases: moving to clinical practice. *Eur Respir J* 2017; 50: 1701655.
- 20 Rutgers SR, Timens W, Kaufmann HF, *et al.* Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. *Eur Respir J* 2000; 15: 109–115.
- 21 Singh D, Kolsum U, Brightling CE, *et al.* Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J* 2014; 44: 1697–1700.
- 22 Kolsum U, Donaldson GC, Singh R, *et al.* Blood and sputum eosinophils in COPD; relationship with bacterial load. *Respir Res* 2017; 18: 88.
- 23 Boersma M, Lutter R, van de Pol MA, *et al.* Repeatability of inflammatory parameters in induced sputum of COPD patients. *COPD* 2007; 4: 321–329.
- 24 Brightling CE, Monterio W, Green RH, *et al.* Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. *Respir Med* 2001; 95: 999–1002.
- 25 Eltboli O, Mistry V, Barker B, *et al.* Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. *Respirology* 2015; 20: 667–670.
- 26 Landis SH, Suruki R, Hilton E, *et al.* Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. *COPD* 2017; 14: 382–388.
- 27 Southworth T, Beech G, Foden P, *et al.* The reproducibility of COPD blood eosinophil counts. *Eur Respir J* 2018; 52: 1800427.
- 28 Yun JH, Lamb A, Chase R, *et al.* Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2018; 141: 2037–2047.
- 29 Oshagbemi OA, Burden AM, Braeken DCW, *et al.* Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. *Am J Respir Crit Care Med* 2017; 195: 1402–1404.
- 30 Casanova C, Celli BR, de-Torres JP, *et al.* Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. *Eur Respir J* 2017; 50: 1701162.
- 31 Landis S, Suruki R, Maskell J, *et al.* Demographic and clinical characteristics of COPD patients at different blood eosinophil levels in the UK Clinical Practice Research Datalink. *COPD* 2018; 15: 177–184.
- 32 Bafadhel M, Peterson S, De Blas MA, *et al.* Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018; 6: 117–126.
- 33 Pavord ID, Lettis S, Locantore N, *et al.* Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax* 2016; 71: 118–125.
- 34 Wedzicha JA, Banerji D, Chapman KR, *et al.* Indacaterol–glycopyrronium *versus* salmeterol–fluticasone for COPD. *N Engl J Med* 2016; 374: 2222–2234.

- 35 Roche N, Chapman KR, Vogelmeier CF, *et al.* Blood eosinophils and response to maintenance COPD treatment: data from the FLAME trial. *Am J Respir Crit Care Med* 2017; 195: 1189–1197.
- 36 Papi A, Kostikas K, Wedzicha JA, *et al.* Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. *Am J Respir Crit Care Med* 2018; 197: 1223–1226.
- 37 Watz H, Tetzlaff K, Wouters EF, *et al.* Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med* 2016; 4: 390–398.
- 38 Chapman KR, Hurst JR, Frent SM, *et al.* Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. *Am J Respir Crit Care Med* 2018; 198: 329–339.
- 39 Pavord ID, Lettis S, Anzueto A, *et al.* Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. *Lancet Respir Med* 2016; 4: 731–741.
- 40 Bafadhel M, McKenna S, Terry S, *et al.* Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. *Am J Respir Crit Care Med* 2012; 186: 48–55.
- 41 Vedel-Krogh S, Nielsen SF, Lange P, *et al.* Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. *Am J Respir Crit Care Med* 2016; 193: 965–974.
- 42 Hastie AT, Martinez FJ, Curtis JL, *et al.* Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med* 2017; 5: 956–967.
- 43 Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS *versus* LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. *Lancet Respir Med* 2018; 6: 855–862.
- 44 Singh D, Ferguson GT, Bolitschek J, *et al.* Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. *Respir Med* 2015; 109: 1312–1319.
- 45 Mahler DA, Decramer M, D’Urzo A, *et al.* Dual bronchodilation with QVA149 reduces patient-reported dyspnea in COPD: BLAZE study. *Eur Respir J* 2014; 43: 1599–1609.
- 46 Martinez FJ, Calverley PM, Goehring UM, *et al.* Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet* 2015; 385: 857–866.
- 47 Albert RK, Connett J, Bailey WC, *et al.* Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011; 365: 689–698.
- 48 Rabe KF, Hurd S, Anzueto A, *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007; 176: 532–555.